Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,832,711
  • Shares Outstanding, K 117,597
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 808 M
  • EBITDA $ 886 M
  • 60-Month Beta 0.94
  • Price/Sales 7.29
  • Price/Cash Flow 15.72
  • Price/Book 17.07

Options Overview Details

View History
  • Implied Volatility 38.45% (-1.11%)
  • Historical Volatility 33.72%
  • IV Percentile 60%
  • IV Rank 30.45%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 7) 4.88 (6.76%)
  • Put/Call Vol Ratio 1.75
  • Today's Volume 782
  • Volume Avg (30-Day) 505
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 12,977
  • Open Int (30-Day) 15,090
  • Expected Range 67.25 to 77.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.84
  • Number of Estimates 4
  • High Estimate 1.95
  • Low Estimate 1.74
  • Prior Year 1.19
  • Growth Rate Est. (year over year) +54.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.22 +17.81%
on 12/11/25
75.59 -4.58%
on 01/07/26
+9.25 (+14.71%)
since 12/08/25
3-Month
61.22 +17.81%
on 12/11/25
75.59 -4.58%
on 01/07/26
+6.93 (+10.63%)
since 10/08/25
52-Week
47.50 +51.85%
on 05/14/25
79.50 -9.27%
on 09/23/25
+18.37 (+34.17%)
since 01/08/25

Most Recent Stories

More News
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Agreement provides Takeda with exclusive access to ENHANZE ® drug delivery technology for vedolizumab

HALO : 72.13 (-3.97%)
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

HALO : 72.13 (-3.97%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9916 (+3.23%)
IDYA : 36.43 (-3.78%)
ZLAB : 18.50 (-2.79%)
CHRS : 1.5300 (+6.99%)
HALO : 72.13 (-3.97%)
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration...

SKYE : 1.0500 (-5.41%)
HALO : 72.13 (-3.97%)
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

SKYE : 1.0500 (-5.41%)
HALO : 72.13 (-3.97%)
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

HALO : 72.13 (-3.97%)
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

RYBREVANT FASPRO ™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)

HALO : 72.13 (-3.97%)
Jim Lang Elected to Halozyme's Board of Directors

SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings...

HALO : 72.13 (-3.97%)
Stocks Settle Mixed on Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.10%....

PATH : 16.88 (-5.38%)
DG : 144.00 (+0.34%)
HRL : 22.87 (+2.37%)
TXN : 188.45 (+1.48%)
$IUXX : 25,507.10 (-0.57%)
SAIC : 111.98 (+4.81%)
ASML : 1,194.32 (-2.78%)
ZNH26 : 112-070 (-0.03%)
COST : 915.31 (+3.71%)
FIVE : 198.01 (-1.30%)
ESH26 : 6,967.75 (+0.08%)
GFS : 38.91 (-4.16%)
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering...

HALO : 72.13 (-3.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 77.86
2nd Resistance Point 76.68
1st Resistance Point 74.41
Last Price 72.13
1st Support Level 70.96
2nd Support Level 69.78
3rd Support Level 67.51

See More

52-Week High 79.50
Last Price 72.13
Fibonacci 61.8% 67.28
Fibonacci 50% 63.50
Fibonacci 38.2% 59.72
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar